Neuroendocrine Tumors
Conditions
Keywords
Neuroendocrine Tumors, Lutetium, Treatment Outcome
Brief summary
Well-differentiated neuroendocrine tumors (WDNETs) are uncommon neoplasms with an increasing number of new cases reported in the annual statistics of the Instituto Nacional de Cancerología (INC). The majority are advanced-stage presentations with limited chances of a complete surgical resection of the primary tumor, a clinical scenario where medical treatment options are also limited. In view of the characteristically defined expression of peptide receptors in WDNETs, radioactive molecular probes to target specific cellular receptors have been designed using radioisotopes with short range of penetration in tissues. We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-\[DOTA 0, Tyr 3\] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET. Selected patients matching inclusion criteria will be enrolled at the INC's Section of Endocrinology. Tumor response, treatment safety (side effects) and survival will be appraised. Data from clinical, biochemical and imaging follow-up will be periodically registered during treatment and until two years after the last infusion of 177Lu- DOTATATE. This phase II trial is justified because despite the fact that many preclinical and clinical studies have showed the potential usefulness of this novel palliative approach to treat patients with advanced-stage WDNETs there is a paucity of vigorous results to establish its efficacy as first-line treatment.
Detailed description
The Investigators have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-\[DOTA 0, Tyr 3\] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
Interventions
RADIATION[177Lu] DOTA-TATE
We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-\[DOTA 0, Tyr 3\] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
Sponsors
Instituto Nacional de Cancerologia, Columbia
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients with inoperable gastroenteropancreatic neuroendocrine tumors. * Histopathologic diagnosis confirmed at the Instituto Nacional de Cancerología. * Somatostatin receptor-positive tumors with at least one site of abnormal focal uptake \> liver physiologic uptake (3+) observed in a 99mTc-HYNIC-TOC scintigraphy practiced less than 6 months before treatment with 177Lu- DOTATATE. * Karnofsky functional score \> 60. * Life expectancy \> 3 months. * Multiple inoperable metastatic sites. * Patient voluntarily willing to participate in the trial. * Hemoglobin (Hb) \> 8.8 g/dl * Leucocytes (Leu) \> 2 x 103/µl * Platelets (Plaq) \> 80 x 103/µl * Total Bilirrubin (BT) ≤ 3 times the upper limit of normal range. Serum albumin \> 3 g/dl and normal prothrombin time. * At least one measurable CT tumor lesion. * Non-lactating woman with negative pregnancy blood test. * Creatinine clearance \> 40 ml/min and serum creatinine \< 1.5 mg/dl and/or isotopic glomerular filtration rate \> 50 ml/min. * Test results should predate treatment by at least: blood test results ≤ 4 weeks, liver blood tests \< 1 month, renal function tests \< 1 week, CT ≤ 4 months and 99mTc-HYNIC-TOC scintigraphy \< 6 months.
Exclusion criteria
* Patients previously treated with radionuclide therapy. * Patients treated with chemo- o radiotherapy within the past 6 months. * Patients unable to comply with clinical follow-up in both Nuclear Medicine and Endocrinology units. * Patients unwilling to participate in the trial or not providing written informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response to treatment | 3 years | Response to palliative treatment with 177Lu- DOTATATE in patients with metastatic progressive low-grade neuroendocrine tumors defined by control size tumor, response time to reduction minimal parcial and complete tumor. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy defined by reduction in size tumoral | 3 years | Measure the efficacy of 177Lu- DOTATATE to treat patients with metastatic progressive low-grade neuroendocrine tumors using clinical and imaging criteria such as tumor size. |
| Side effects defined by clinical follow up | 5 years | Describe the side effects of the treatment with 177Lu- DOTATATE by clinical follow-up during and after therapy |
| survival rate | 2 years | describe the 2-year survival rate of patients treated with 177Lu- DOTATATE |
| Quality of life | 3 years | Assess the quality of life of patients with metastatic progressive low-grade neuroendocrine tumors treated with 177Lu- DOTATATE during treatment defined by pain reduction and tolerability. |
Countries
Colombia
Outcome results
None listed